- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01811316
A Clinical Trial to Evaluate Long-term Efficacy and Safety of Lozenges Containing Lactobacilli Reuteri (Prodentis™) on Gingivitis
Studienübersicht
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Massachusetts
-
Cambridge, Massachusetts, Vereinigte Staaten, 02142
- The Forsyth Institute
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Willing and able to read, understand and sign an Informed Consent form.
- Good general health as evidenced by the medical history.
- Between 18 and 65 years of age.
- Male or female.
- Minimum of 20 teeth, excluding crowns and third molar teeth.
- Mean whole mouth Modified Gingival Index of greater-than or equal to 2.0 at baseline.
- Willing to abstain from all oral hygiene procedures for 12-18 hours prior to clinical visits.
- Willing to abstain from eating and drinking in the morning of visits, only drinking water is allowed.
- Willing to abstain from interdental cleaning, chewing gums, oral whitening, mouth rinse and tobacco products for the study duration.
- Able to understand and follow study directions.
- No known history of allergy to dairy products or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study.
Exclusion Criteria
- Presence of orthodontic appliances.
- Intra-oral soft tissue lesions due to pathology or trauma
- Patients with aggressive periodontitis, acute necrotizing ulcerative gingivitis, or gross decay at discretion of PI.
- More than two sites with pocket depth >5mm and concomitant attachment loss of >2mm.
- Pregnant or lactating females or females of child bearing potential not using acceptable methods of birth control (hormonal, barriers or abstinence).
- Use of antibiotics within 3 months of enrollment
- History of drug use that is associated with gum overgrowth (i.e., Dilantin, nifedipine, etc)
- Chronic use of medication such as steroids, NSAIDs (more than 2-3 days/week), anti-coagulant medications, immunosuppressant medications or any other medications that in the opinion of the Investigator would interfere with the evaluation or confound interpretation of the study results. Use of low dose of acetylsalicylic acid (81 mg) is permitted.
- Unwilling to sign a confidentiality statement and/or return the test products.
- Medical condition which requires pre-medication prior to dental visits/procedures.
- Immune compromised individuals (HIV, AIDS, immunosuppressive drug therapy).
- Current use of probiotics or probiotic containing food (i.e., yogurt)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Probiotics Lozenge (twice a day)
Subjects take their lozenge twice a day, one lozenge in the morning after brushing and one lozenge in the evening after brushing.
|
|
|
Aktiver Komparator: Probiotics Lozenge (once a day)
Subjects take their lozenge once a day, one lozenge at night after brushing.
|
|
|
Placebo-Komparator: Placebo Lozenge (once a day)
Subjects take their lozenge once a day, one lozenge at night after brushing.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change From Baseline in Modified Gingival Index (MGI)
Zeitfenster: 4, 12 and 24 weeks
|
Modified Gingival Index (MGI) (Lobene, Weatherford et al. 1986) was measured on six gingival areas of all scorable teeth, using a scale of 0-4 as follows: Scores Criteria 0 Normal (absence of inflammation)
Whole mouth MGI scores were calculated by summing all scores and dividing by the number of examined scorable sites. |
4, 12 and 24 weeks
|
|
Change From Baseline in Bleeding on Probing (BOP)
Zeitfenster: 4, 12 and 24 weeks
|
Bleeding on probing was assessed 30 seconds after probing.
A dichotomous scoring system was used at six sites per tooth using one (1) and zero (0) for presence or absence, respectively.
BOP (%) is a percentage of sites BOP.
|
4, 12 and 24 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change From Baseline in Plaque Index (PI)
Zeitfenster: 4, 12 and 24 weeks
|
Plaque Index of Turesky Modification of Quigley-Hein (Turesky, Gilmore et al. 1970) (PI) was scored on all natural teeth (except third molars) after disclosing with erythrosine solution. Scores Criteria: 0 No plaque
|
4, 12 and 24 weeks
|
|
Change From Baseline in Probing Depth (PD)
Zeitfenster: 4, 12 and 24 weeks
|
Periodontal pocket depth (PD) was determined with a periodontal probe at six sites per tooth rounded to the next lower whole mm.
|
4, 12 and 24 weeks
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change From Baseline in Inflammatory Markers in Gingival Crevicular
Zeitfenster: 15 days, 4, 12 and 24 weeks
|
Gingival Crevicular Fluid (GCF) samples will be analyzed for inflammatory cytokines/chemokines and matrix metalloproteases using multiplexing ELISA.
|
15 days, 4, 12 and 24 weeks
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Hatice Hasturk, DDS, PhD, The Forsyth Institute
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CLP-2013-1-23
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .